BCL2 and acute myeloid leukemia: In fact, nine new AML therapeutics – including inhibitors of B-cell lymphoma 2 (BCL2), FMS-like tyrosine kinase 3 (FLT3), and isocitrate dehydrogenase (IDH) – were approved by the FDA between 2017 and 2021 (1, 3).